Hints and tips:
Related Special Reports
...Roche has cut a fifth of its drug pipeline in six months, shedding prospective cancer and neurology treatments as the Swiss company seeks to revitalise its business under new chief executive Thomas Schinecker...
...The approval of Madrigal’s drug should help other treatments to pass regulatory hurdles, according to analysts at investment bank William Blair....
...People who will receive treatment with Emblaveo will include very frail patients, those with severe infections or with few other treatment options, and those in regions where drug-resistant bacteria are...
...“Even in an expert treatment centre like ours, it requires a heavy lift in terms of resources and rallying the hospital system to implement these drugs,” said Prof Gil Rabinovici, a neurologist at San Francisco...
...treatment of Alzheimer’s Alzheimer’s Disease affects a person’s neurons....
There is still room for growth in Japan’s $53bn dispensing pharmacy market
...to cover the treatment....
...AstraZeneca has reported successful trial results for one of its top cancer drugs, in a boost to the drugmaker’s ambitions for its medication to be a treatment option for more than half of lung cancer patients...
...Both groups are studying the drugs as treatments for different types of fatty liver diseases....
...Finding an effective treatment for Alzheimer’s has proved fiendishly difficult for drug companies, and previous regulatory decisions in the field have stirred controversy....
...AstraZeneca unveiled successes in the treatment of lung cancer on Monday, with its leading drug slowing progression of the disease at an early stage....
...Novo Nordisk is trialling GLP-1 treatments on conditions including cardiovascular diseases and Alzheimer’s, but the lixisenatide trial is one of the first longer studies to suggest that a GLP-1 drug may...
...Scotland approved the drug for advanced cancer treatment in December, creating a “heartbreaking postcode lottery of access”, the charity said....
...Among the most expensive approved gene therapies are uniQure’s haemophilia B treatment Hemgenix, at $3.5mn and Bluebird’s thalassaemia drug Zynteglo, which is priced at $2.8mn....
...Soleno Therapeutics, a rival biotech which is expected to file for US Food and Drug Administration approval for another treatment for Prader-Willi syndrome later this year, is currently valued at nearly...
...About one in five of the 105 obesity treatments being developed are also being tested for MASH, according to the Stat obesity drug tracker....
...Both are now aiming to cement their leadership in weight-loss drugs: between them they have five new, and potentially more effective. treatments in phase 3 trials....
...You may wish to draw a diagram Distinguish between typical and atypical drugs as used in the treatment of schizophrenia Explain two limitations of drug therapy for schizophrenia The article gives Indivior...
...The developer of a rival weight-loss treatment to those offered by Novo Nordisk and Eli Lilly said its drug had achieved positive results in liver disease trials, showing how a new class of obesity drugs...
...Scientists have invented a potential drug candidate that successfully combats antibiotic-resistant “superbugs” in non-human tests, according to research....
...The company said the decision was partly driven by huge demand for weight-loss drugs....
...Around 1,000 people in England would be eligible for the treatment each year, according to charity Breast Cancer Now....
...Sales of its diabetes and obesity drugs have sent Novo Nordisk’s market capitalisation soaring but the company has also set a goal of diversifying, including into the treatment of cardiovascular diseases...
...Since leaving the European Union in January 2020, the UK has faced “constantly elevated medicines shortages” including for key treatments such as antibiotics and epilepsy drugs, the think-tank said on Thursday...
...OCD How much does it cost to develop a new drug treatment?...
International Edition